The prevalence of NAFLD increases by a factor of 4.6 in obese people, defined as those with a body-mass index of at least 30 [
12]. Considering the increasing prevalence of obesity among adults and children [
13], steatosis may soon become a greater issue. In the present study involving 227 lymphoma patients over a period of 1 year, hepatic steatosis was observed in 11.9% of the patients at some point during their baseline or post-treatment evaluation. This is less than the prevalence observed in the general population and could certainly be explained by the cut-off of 42 HU used to discriminate steatotic versus non-steatotic patients. Indeed, the use of this cut-off value enables the diagnosis of macrovesicular steatosis of 30% or greater. Therefore, mild macrovesicular steatosis (<30%) was not considered in the present study. Yet, by virtue of higher fatty than hepatic parenchymal density, this cut-off value permits an easy recognition of steatosis on the non-contrast CT component of a PET/CT and can easily be performed in clinical practice. Interestingly, post-treatment hepatic steatosis was not apparently related to the type of chemotherapy regimen, nor to the time-course of treatment and therefore does not explain the variability of liver
18F–FDG uptake previously observed in patients with DLBCL and HL [
14].
18F-FDG PET/CT has already been explored in the context of hepatic steatosis but never in a population of lymphoma patients. These previous studies led to contradictory results with positive [
15], negative [
16] or even no relationship [
17] between hepatic steatosis and liver SUVs. This could potentially be explained by other factors influencing the liver uptake, such as BMI, which is definitely linked to hepatic steatosis [
18], not being considered. However, Lin’s results were in accordance with ours [
16] and in the same line Abele et al., observed lower SUV
mean in steatotic patients even though statistical significance was not reached [
17]. The study showing a positive relationship between steatosis and SUV
max did not actually take into account patients BMI, and; therefore, these results were certainly biased [
15]. In our study, BMI and BGL appeared to be statistically different between steatotic and non-steatotic groups of patients whereas other parameters described as potentially affecting hepatic uptake {age, sex, treatment, time course of treatment [
14,
19‐
21]} were not. Concerning BGL, a proportional relationship with
18F–FDG liver uptake has been shown, even for blood glucose in line with EANM recommendations [
22]. However, in our study, liver SUL
max values were not significantly linked to BGL recorded at injection time for either interim or EoT PET scans. To take into account the BMI, which is the main confounding parameter regarding steatosis, we used liver SUL
max values instead of the recommended SUV
max values for the determination of Deauville Scores [
11]. However, according to the EANM procedure guidelines for tumour imaging [
22], SUL is a recommended quantitative measure of
18F-FDG uptake and, in our study, SUL
max values gave the same DS as SUV
max values in almost all cases except in two examinations among 215 interim and EoT PET examinations (0.9%). Furthermore, these corresponded to changes between DS 4 and 5 or DS 2 and 3, meaning no change between responder versus non-responder status. These results suggest that either SUV
max or SUL
max can be used to score patients with relatively consistent results. However, the use of SUL
max has the advantage of giving the opportunity to reveal and potentially take into account parameters other than BMI that could influence the liver uptake, such as steatosis in the present case.
Liver SUL
max values were significantly lower in the presence of hepatic steatosis (defined as a mean liver density ≤ 42 HU) in both interim and EoT PET scans with an average decrease of 29.5% and 29.9%, respectively (Fig.
3a). Liver SUV
max values were also significantly lower in the presence of hepatic steatosis in EoT PET scans of normal-weight and overweight patients (BMI < 30 kg/m
2) with an average decrease of 21.1% (Fig.
6a). The same results were not observed in obese patients (BMI ≥ 30 kg/m
2) underlining the fact that this group clearly benefit from the use of SUL instead of SUV values that do not take into account the absence of
18F–FDG uptake in adipose tissue. One could thus expect a possible overestimation of the DS in steatotic patients from DS3 to DS4 with the risk of inducing erroneous modifications in patients’ management. Indeed, being classified as a non-responder (DS4) on an EoT PET usually prompts the use of a subsequent line of chemotherapy. Another important finding is that liver HU
mean values were the only independent factor correlated to liver SUL
max values in interim and EoT groups (Table
3) which allowed us to successfully correct liver SUL
max values by using a graphical method (Fig.
5) based on the slope of the calculated linear regression. Importantly, the application of this liver SUL
max correction led to the reclassification of all steatotic patients scored DS4 to DS3. Given the small number of steatotic patients scored DS4 on interim and EoT PET scans in our series, it is not possible to assess the clinical impact and veracity of these changes with respect to therapeutic intervention or patient outcome. Larger and more homogeneous studies are needed to substantiate the advantage of correcting the liver uptake of steatotic patients initially scored DS4. Our findings could also be confirmed in trials with homogeneously treated patients for which central reviewing has been performed. For instance, in the IELSG-26 study in patients with primary mediastinal DLBLC [
23], the rate of DS4 was 24/115 (21%) and in a recent trial in advanced HL [
24], it was 144/1119 (12.9%). However, at the present time, attention should be paid to the interpretation of the PET examinations scored DS4 with a percentage difference between the target lesion and the liver background lower than 30%, which is the average decrease in our series, and steatosis should be sought for on the CT part of the PET/CT examination to avoid erroneous alteration of patient’ management. When steatosis is depicted, the application of a correction as described in the results section or the use of delta SUL should be considered.